View Transcript
Episode Description
Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson’s disease and outlines Phase II plans for the company’s lead asset HER-096.
See all episodes
Never lose your place, on any device
Create a free account to sync, back up, and get personal recommendations.
Chapters
0 Chapters